{
    "ticker": "INBX",
    "name": "InhibRx, Inc.",
    "description": "InhibRx, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with cancer and autoimmune diseases. Founded in 2018 and headquartered in Gaithersburg, Maryland, InhibRx is committed to advancing its novel monoclonal antibody therapies, particularly its lead product candidate, Abivertinib, which is designed to inhibit specific signaling pathways involved in disease progression. The company's research emphasizes the need for targeted and effective treatment options that can improve patient outcomes while minimizing side effects. InhibRx aims to leverage its proprietary technology platform to identify and optimize therapeutic candidates for a range of indications, including solid tumors and autoimmune disorders. With a strong emphasis on scientific rigor and collaboration, InhibRx is working towards bringing transformative therapies to market that can make a significant difference in the lives of patients. The company is actively pursuing clinical trials to evaluate the safety and efficacy of its drug candidates, and it seeks to build strategic partnerships to enhance its research capabilities and expand its therapeutic pipeline. InhibRx is dedicated to its mission of addressing unmet medical needs and making a meaningful impact in the biopharmaceutical landscape.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Gaithersburg, Maryland, USA",
    "founded": "2018",
    "website": "https://www.inhibrx.com",
    "ceo": "Dr. David A. Ricks",
    "social_media": {
        "twitter": "https://twitter.com/InhibRx",
        "linkedin": "https://www.linkedin.com/company/inhibrx/"
    },
    "investor_relations": "https://www.inhibrx.com/investor-relations",
    "key_executives": [
        {
            "name": "Dr. David A. Ricks",
            "position": "CEO"
        },
        {
            "name": "Dr. Robert J. W. H. Houghton",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "Abivertinib"
            ]
        }
    ],
    "seo": {
        "meta_title": "InhibRx, Inc. | Innovative Therapies for Cancer and Autoimmune Diseases",
        "meta_description": "InhibRx, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for cancer and autoimmune diseases. Learn more about our mission and product pipeline.",
        "keywords": [
            "InhibRx",
            "Biopharmaceuticals",
            "Cancer Therapy",
            "Autoimmune Disease",
            "Abivertinib"
        ]
    },
    "faq": [
        {
            "question": "What does InhibRx focus on?",
            "answer": "InhibRx focuses on developing innovative therapies for cancer and autoimmune diseases."
        },
        {
            "question": "Who is the CEO of InhibRx?",
            "answer": "Dr. David A. Ricks is the CEO of InhibRx, Inc."
        },
        {
            "question": "Where is InhibRx headquartered?",
            "answer": "InhibRx is headquartered in Gaithersburg, Maryland, USA."
        },
        {
            "question": "What is InhibRx's lead product candidate?",
            "answer": "InhibRx's lead product candidate is Abivertinib."
        },
        {
            "question": "When was InhibRx founded?",
            "answer": "InhibRx was founded in 2018."
        }
    ],
    "competitors": [
        "BMY",
        "NVS",
        "AMGN",
        "JAZZ"
    ],
    "related_stocks": [
        "MRNA",
        "PFE",
        "GILD",
        "VRTX"
    ]
}